Category - Markets

Markets

Roth starts Forty Seven at buy; PT $28

Roth Capital Partners initiated coverage of Forty Seven (NASDAQ:FTSV) with a “buy” rating and $28 price target. The stock closed at $12.49, up 34 cents, on May 28.

May 29, 2019

Markets

Roth starts Five Prime Therapeutics at neutral; PT $10

Roth Capital Partners launched coverage of Five Prime Therapeutics (NASDAQ:FPRX) with a “neutral” rating and $10 price target. The stock closed at $8.73, down 32 cents, on May 28.

May 29, 2019

Markets

Roth starts Corvus Pharma at buy; PT $6

Roth Capital Partners launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with a “buy” rating and price target of $6. The stock closed at $3.90 on May 28.

May 29, 2019

Markets

SVB Leerink transfers coverage of Alder BioPharma at OP; PT $21

Analyst Marc Goodman of SVB Leerink has assumed coverage of Alder BioPharmaceuticals (NASDAQ:ALDR) with an “outperform” rating and $21 price target. The stock closed at $11.06 on May 24.

May 28, 2019

Markets

Novo Holdings to acquire up to 10.1% in Oxford Biomedica

Novo Holdings A/S has agreed to invest up to £53.5 million in Oxford Biomedica plc (LSE:OXB) in return for new ordinary shares, representing up to 10.1% of the outstanding shares after a capital increase.

May 28, 2019

Markets

Canaccord starts TransMedics at buy; PT $37

Canaccord Genuity initiated coverage of TransMedics Group (NASDAQ:TMDX) with a “buy” rating and price target of $37. The stock closed at $28.88 on May 24.

May 28, 2019

Markets

Mackie Research cuts Medicure to hold; PT to $6.50 from $7.60

Mackie Research Capital downgraded Medicure (TSXV:MPH) to “hold from “buy” and cuts its price target to $6.50 from $7.60 after the company reported weaker than expected first quarter results. The stock closed at $5.99...

May 28, 2019

Markets

Paradigm starts Cansortium at buy; PT $2.40 to $3.40

Paradigm launched coverage of Cansortium (CSE:TIUM) with a “buy” rating and a price target between $2.40 and $3.40. The stock closed at $1.59 on May 23.

May 24, 2019

Markets

HCW ups Aurinia price target to $25

H.C. Wainwright raised its price target for Aurinia Pharmaceuticals (NASDAQ:AUPH) to $25 from $15 after assessing the value of the company’s recently-received new dosing regimen patent. The stock closed at $6.49 on May...

May 23, 2019

Markets

HCW starts Aeglea BioTherapeutics at buy; PT $20

H.C. Wainwright launched coverage of Aeglea BioTherapeutics (NASDAQ:AGLE) with a “buy” rating and $20 price target. The stock closed at $6.92 on May 21.

May 22, 2019

Category - Markets

Roth starts Forty Seven at buy; PT $28

Roth starts Five Prime Therapeutics at neutral; PT $10

Roth starts Corvus Pharma at buy; PT $6

SVB Leerink transfers coverage of Alder BioPharma at OP; PT $21

Novo Holdings to acquire up to 10.1% in Oxford Biomedica

Canaccord starts TransMedics at buy; PT $37

Mackie Research cuts Medicure to hold; PT to $6.50 from $7.60

Paradigm starts Cansortium at buy; PT $2.40 to $3.40

HCW ups Aurinia price target to $25

HCW starts Aeglea BioTherapeutics at buy; PT $20

General

More